Literature DB >> 16391861

TGF-beta1-induced cell growth arrest and partial differentiation is related to the suppression of Id1 in human hepatoma cells.

Bazarragchaa Damdinsuren1, Hiroaki Nagano, Motoi Kondo, Javzandulam Natsag, Hiroyuki Hanada, Masato Nakamura, Hiroshi Wada, Hitoshi Kato, Shigeru Marubashi, Atsushi Miyamoto, Yutaka Takeda, Koji Umeshita, Keizo Dono, Morito Monden.   

Abstract

Transforming growth factor beta 1 (TGF-beta1) is a proposed regulator of Ids (inhibitors of DNA binding/differentiation) gene expression in epithelial cells. We previously reported that Id proteins are variously expressed in human hepatocellular carcinomas (HCC). However, the mechanism of regulation of Ids in HCC remains obscure. Here, we examined the relationship between Id1 and TGF-beta1 in four HCC cell lines, and studied the changes in cell proliferation, cell cycle and differentiation. The four HCC cell lines expressed Id1, TGF-beta1 and their receptors at various levels. TGF-beta1 strongly inhibited the growth of HuH7 cells, while the growth inhibition was moderate in PLC/PRF/5, and was not observed in HLE and HLF cell lines. TGF-beta1-induced growth inhibition in HuH7 cells was associated with cell accumulation in the G1 phase and partial induction of differentiation (with reduction of AFP and AFP-L3). Induction by TGF-beta1 dose-dependently suppressed Id1 expression in HuH7 cells; 1 ng/ml TGF-beta1 inhibited Id1 by 84.0 and 78.6% that of the untreated control at transcriptional and protein levels, respectively. HLE and HLF cells, which did not exhibit a TGF-beta1 growth inhibitory effect, lacked TGF-beta receptors and Id1 expression was not altered. In PLC/PRF/5 cells, Id1 augmentation was not observed in response to TGF-beta1, indicating that TGF-beta1-induced growth inhibition was not related to Id1 in this cell line. Our results suggest that, in some HCC cells, the pathway of suppression of Id1 by TGF-beta1 may be important in TGF-beta1-induced growth inhibition and partial differentiation.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16391861

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  9 in total

1.  Transforming growth factor-β decreases side population cells in hepatocellular carcinoma in vitro.

Authors:  Jong Bin Kim; Seulki Lee; Hye Ri Kim; Seo-Young Park; Minjong Lee; Jung-Hwan Yoon; Yoon Jun Kim
Journal:  Oncol Lett       Date:  2018-04-05       Impact factor: 2.967

2.  HEY2 acting as a co-repressor with smad3 and smad4 interferes with the response of TGF-beta in hepatocellular carcinoma.

Authors:  Jianqing Wang; Bo Zhu; Yuanyuan Zhang; Hexige Saiyin; Reziya Wumaier; Long Yu; Lichun Sun; Qianyi Xiao
Journal:  Am J Transl Res       Date:  2019-07-15       Impact factor: 4.060

3.  Induced differentiation of hepatocellular carcinoma by natural products.

Authors:  Xiong-Zhi Wu; Guang-Ru Xie
Journal:  Afr J Tradit Complement Altern Med       Date:  2008-06-18

4.  ID1, inhibitor of differentiation/DNA binding, is an effector of the p53-dependent DNA damage response pathway.

Authors:  Yingjuan Qian; Xinbin Chen
Journal:  J Biol Chem       Date:  2008-06-13       Impact factor: 5.157

5.  Integrated analysis of the heterogeneous microarray data.

Authors:  Sung Gon Yi; Taesung Park
Journal:  BMC Bioinformatics       Date:  2011-07-27       Impact factor: 3.169

6.  siRNA-mediated knockdown of ID1 disrupts Nanog- and Oct-4-mediated cancer stem cell-likeness and resistance to chemotherapy in gastric cancer cells.

Authors:  Linlin Li; Xiaoyong Wei; Baofeng Wu; Yuanli Xiao; Mingzhu Yin; Qiaohong Yang
Journal:  Oncol Lett       Date:  2017-03-08       Impact factor: 2.967

7.  Inhibitor of differentiation 1 (ID1) promotes cell survival and proliferation of prostate epithelial cells.

Authors:  Michelle Schmidt; Ananthi J Asirvatham; Jaideep Chaudhary
Journal:  Cell Mol Biol Lett       Date:  2010-02-25       Impact factor: 5.787

8.  Activation of Wnt/beta-catenin signalling pathway induces chemoresistance to interferon-alpha/5-fluorouracil combination therapy for hepatocellular carcinoma.

Authors:  T Noda; H Nagano; I Takemasa; S Yoshioka; M Murakami; H Wada; S Kobayashi; S Marubashi; Y Takeda; K Dono; K Umeshita; N Matsuura; K Matsubara; Y Doki; M Mori; M Monden
Journal:  Br J Cancer       Date:  2009-04-28       Impact factor: 7.640

9.  CD133: a stem cell biomarker and beyond.

Authors:  Zhong Li
Journal:  Exp Hematol Oncol       Date:  2013-07-01
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.